Reply to T.J.A. Dekker.

J Clin Oncol

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Haeseong Park, MD, MPH, Washington University School of Medicine, St Louis, MO; Rashmi K. Murthy, MD, MBE, University of Texas MD Anderson Cancer Center, Houston, TX; Hiroji Iwata, PhD, MD, Aichi Cancer Center Hospital, Nagoya, Japan; Kenji Tamura, MD, PhD, National Cancer Center Hospital, Tokyo, Japan; Junji Tsurutani, MD, PhD, Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan and Kindai University Faculty of Medicine, Osaka, Japan; Alvaro Moreno-Aspitia, MD, Mayo Clinic, Jacksonville, FL; Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan; Yasuaki Sagara, MD, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan; Charles Redfern, MD, Sharp HealthCare, San Diego, CA; Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute, Boston, MA; Caleb Lee, MD, PhD, Daiichi Sankyo, Basking Ridge, NJ; Yoshihiko Fujisaki, MS and Masahiro Sugihara, PhD, Daiichi Sankyo, Tokyo, Japan; Lin Zhang, MD, PhD and Javad Shahidi, MD, Daiichi Sankyo, Basking Ridge, NJ; and Shunji Takahashi MD, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

Published: October 2020

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.20.01212DOI Listing

Publication Analysis

Top Keywords

reply tja
4
tja dekker
4
reply
1
dekker
1

Similar Publications

Reply to T.J.A. Dekker.

J Clin Oncol

October 2020

Shanu Modi, MD, Memorial Sloan Kettering Cancer Center, New York, NY; Haeseong Park, MD, MPH, Washington University School of Medicine, St Louis, MO; Rashmi K. Murthy, MD, MBE, University of Texas MD Anderson Cancer Center, Houston, TX; Hiroji Iwata, PhD, MD, Aichi Cancer Center Hospital, Nagoya, Japan; Kenji Tamura, MD, PhD, National Cancer Center Hospital, Tokyo, Japan; Junji Tsurutani, MD, PhD, Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan and Kindai University Faculty of Medicine, Osaka, Japan; Alvaro Moreno-Aspitia, MD, Mayo Clinic, Jacksonville, FL; Toshihiko Doi, MD, PhD, National Cancer Center Hospital East, Kashiwa, Japan; Yasuaki Sagara, MD, Social Medical Corporation Hakuaikai Sagara Hospital, Kagoshima, Japan; Charles Redfern, MD, Sharp HealthCare, San Diego, CA; Ian E. Krop, MD, PhD, Dana-Farber Cancer Institute, Boston, MA; Caleb Lee, MD, PhD, Daiichi Sankyo, Basking Ridge, NJ; Yoshihiko Fujisaki, MS and Masahiro Sugihara, PhD, Daiichi Sankyo, Tokyo, Japan; Lin Zhang, MD, PhD and Javad Shahidi, MD, Daiichi Sankyo, Basking Ridge, NJ; and Shunji Takahashi MD, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.

View Article and Find Full Text PDF

The World Health Organization published guidelines in 2016 for preventing surgical site infections. The guidelines contained a conditional recommendation that laminar airflow (LAF) ventilation systems should not be used to reduce the risk of infection after total joint arthroplasty (TJA). This recommendation was largely based on a systematic review and meta-analysis of information from hospital infection surveillance registries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!